ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Mar 26, 2020||ENDRA Life Sciences Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results|
|Mar 19, 2020||ENDRA Life Sciences Provides Update on FDA Regulatory Timeline|
|Mar 17, 2020||ENDRA Life Sciences Provides European Commercialization Update|
|Mar 10, 2020||ENDRA Life Sciences Receives CE Mark for its TAEUS(R) Clinical Product Targeting Non-Alcoholic Fatty Liver Disease|
|Mar 09, 2020||ENDRA Life Sciences to Host Fourth Quarter 2019 Financial Results Conference Call and Webcast on Thursday, March 26, 2020 at 4:30 p.m. ET|
|Day Range||0.5990 - 0.6700|
|52 Week Range||0.5990 - 2.2500|
|Bid/Ask||0.6514 / 0.6690|
|Bid/Ask Size||100 X 4,000|
|Market Cap||5.51 million|
|Shares Outstanding||8.42 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|